Cholinergic Basis for Alzheimer Therapy

Front Matter....Pages i-x
Therapy of the Cognitive Deficit in Alzheimer’s Disease: The Cholinergic System....Pages 1-22
Front Matter....Pages 23-23
Cortical Cholinesterases in Alzheimer’s Disease: Anatomical and Enzymatic Shifts from the Normal Pattern....Pages 25-30
Cholinesterases in Human Degenerative Diseases....Pages 31-37
The Pathology of the Human Nucleus Basalis of Meynert and its Implications for a Specific Therapy....Pages 38-45
Structure-Function Relationship Studies in Human Cholinesterases as an Approach for Evaluating Potential Pharmacotherapeutic and/Or Toxicity Effects of Cholinergic Drugs....Pages 46-52
Structure of the Acetylcholinesterase Gene: Regulation of Its Expression....Pages 53-60
Front Matter....Pages 61-61
Kinetics and Mechanisms of Reversible and Progressive Inhibition of Acetylcholinesterase....Pages 63-67
Clinical Pharmacokinetics of Centrally Acting Cholinesterase Inhibitors....Pages 68-73
Pre- and Postsynaptic Effects of Cholinesterase Inhibitors....Pages 74-81
Front Matter....Pages 83-83
Immunocytochemistry of Muscarinic and Nicotinic Receptors in Human Brain....Pages 85-91
Presynaptic Cholinergic Mechanisms in Human Cerebral Cortex of Adult and Aged Patients....Pages 92-97
Nicotinic Acetylcholine Receptors in the Human Nervous System....Pages 98-106
Nicotinic Receptors in the CNS as Visualized by Positron Emission Tomography....Pages 107-115
Front Matter....Pages 117-117
Nucleus Basalis Lesions and Recovery....Pages 119-125
Experimental Automimmune Dementia (EAD): An Immunological Model of Memory Dysfunction and Alzheimer’s Disease....Pages 126-133
Aging of the Cholinergic Synapse in the Rat’s Hippocampus: Effect of Acetyl-L-Carnitine....Pages 134-140
SDAT Models and Their Dynamics....Pages 141-152
Front Matter....Pages 153-153
Toxicological Limitations to Cholinomimetic Therapy....Pages 155-161
Learning and Memory Enhancement by Drugs which Indirectly Promote Cholinergic Neurotransmission....Pages 162-169
Functional Cholinergic Receptor Sensitivity: The Role of Drug Probes....Pages 170-182
Front Matter....Pages 153-153
Brain Phospholipids and their Metabolites in Alzheimer’s Disease: Possible Role of “Auto-Cannibalism” and Implications for Drug Development....Pages 183-189
Front Matter....Pages 191-191
Galanin: Regulation of Cholinergic Function and Behaviour....Pages 193-199
Activation of the Brain Cholinergic System by Noncholinomimetic Agents....Pages 200-205
Front Matter....Pages 207-207
Physostigmine in Alzheimer’s Disease....Pages 209-215
Swedish Experiences of THA Therapy in Alzheimer’s Disease....Pages 216-223
Status of THA as Therapy for Alzheimer’s Disease....Pages 224-230
Responders and Nonresponders in Experimental Therapy of Alzheimer’s Disease....Pages 231-237
Cholinesterase Inhibitors in Alzheimer’s Disease: Evaluation of Clinical Studies....Pages 238-243
Front Matter....Pages 245-245
The Second Generation of Cholinesterase Inhibitors: Pharmacological Aspects....Pages 247-262
The Second Generation of Cholinesterase Inhibitors: Clinical and Pharmacological Effects....Pages 263-296
Heptylphysostigmine — Novel Acetylcholinesterase Inhibitor: Biochemical and Behavioral Pharmacology....Pages 297-304
Clinical and Preclinical Studies with Huperzine....Pages 305-313
E2020 — The Pharmacology of a Piperidine Cholinesterase Inhibitor....Pages 314-320
Pharmacodynamics of Oral E2020 and Tacrine in Humans: Novel Approaches....Pages 321-328
Preclinical and Clinical Studies with Galanthamine....Pages 329-336
Alzheimer Therapy with Cholinomimetics: The Japanese Experience....Pages 337-343
Front Matter....Pages 345-345
Novel Muscarinic Agonists for the Treatment of Alzheimer’s Disease....Pages 347-353
New Muscarinic Agonists with Special Emphasis on AF102B....Pages 354-362
AF102B: Preclinical Experience....Pages 363-369
Muscarinic Agonists for Senile Dementia: Past Experience and Future Trends....Pages 370-376
Front Matter....Pages 377-377
Some Novel Actions of Nicotine in Nucleus Basalis Lesioned Rats and in Hippocampal Slices....Pages 379-385
New Nicotinic Agonists and Cerebral Blood Flow....Pages 386-394
Front Matter....Pages 395-395
Pharmacological Actions of Recombinant Human Nerve Growth Factor on Lesioned Central Cholinergic Neurons: Rationale for the Treatment of Alzheimer’s Disease....Pages 397-403
Correlation of Cholinergic Functional Stimulation by Exogenous NGF with Aged Rat Behavior....Pages 404-411
Effect of Nerve Growth Factor on Lesioned and Intact CNS....Pages 412-416
Trophic and Modulating Factors for Basal Forebrain Cholinergic Neurons....Pages 417-426
The Effects of Nerve Growth Factor on the Central Nervous System of the Adult Primate....Pages 427-444
Neurotrophic Factor-Induced Presynaptic Morphological and Functional Changes of the Cortical Cholinergic Input....Pages 445-452
Toward the Pharmacological Regulation of Nerve Growth Factor Biosynthesis....Pages 453-459
Nerve Growth Factor and Aging: A Hypothesis....Pages 460-467
New Directions in NGF Experimental Therapy of Alzheimer’s Disease....Pages 468-473
Front Matter....Pages 475-475
Toward a Third Generation of Cholinesterase Inhibitors....Pages 477-490
Back Matter....Pages 491-494